Managed Care Watch
Company findings / Initial collection

Humana

Public spending, contract decisions, workforce disclosures and executive leadership.

Download research workbook
Recent company updates

New developments.

Humana / CenterWell / Corporate transaction

Published 2026-10-13 · Added 2026-10-13

Event date: 2026-10-13

Humana announces new BlackRock joint venture for CenterWell clinics

Humana announced an agreement under which BlackRock-managed funds would acquire WCAS's ownership in joint ventures holding nearly 150 CenterWell Senior Primary Care clinics. CenterWell would retain a minority interest and continue managing and operating the clinics. Humana said the WCAS equity stake is valued at approximately $2.8 billion.

Why it matters: The arrangement could affect financing and future ownership of a large senior-focused primary care network. The transaction is expected to close in the fourth quarter of 2026, subject to state and federal regulatory approval. The $2.8 billion figure is not announced proceeds to Humana, a fine, a contract award or evidence of improved patient access.

Definitive joint venture agreement announced; regulatory approval and closing pending

Humana company release distributed by Business Wire: source

Humana findings
Humana / Medicare quality ratings

Published 2026-10-09 · Added 2026-10-09

Event date: 2026-10-08

Humana reports 95% of Medicare Advantage members in four-star-or-higher 2027 contracts

Humana announced that 95% of its Medicare Advantage members are enrolled in contracts rated at least four stars for 2027, including 42% in 4.5-star contracts. It lists six MA contracts at 4.5 stars and 12 at four stars, plus a 4.5-star prescription drug contract.

Why it matters: The company percentage weights membership rather than counting contracts. CMS ratings measure defined quality and experience indicators, not every denial or individual outcome. Future bonus revenue is not a paid enforcement amount or an established financial recovery. October 10 update: Humana’s October 9 Form 8-K says actual 2028 Stars revenue depends on future membership, contract mix and other inputs. Its affirmed adjusted EPS guidance remains forward-looking, not a realized result.

Company summary of CMS ratings; individual outcomes not independently verified

Humana: source

Additional primary source

Humana findings
Humana / Medicare

Published 2026-10-01 · Added 2026-10-07

Event date: 2026-10-01

Humana outlines 2027 coverage footprint and specialized-plan expansion

Humana announced Medicare Advantage offerings in approximately 2,600 counties across 45 states and Washington, D.C. for 2027. It also announced expansion of chronic-condition special needs plans into Pennsylvania, Utah and Wisconsin.

Why it matters: A national footprint does not show whether a particular member keeps the same plan or clinicians. Check county-level availability and actual benefit and network changes rather than assuming continuity from a company announcement.

Company announcement; future availability

Humana: source

Humana findings

Review completed October 13, 2026. Added Humana's announced CenterWell clinic joint venture with BlackRock. The transaction is pending regulatory approval and the stated $2.8 billion is the value of WCAS's equity stake, not proceeds to Humana or a fine.

CMS and managed care news archive
Analysis

What the documented record shows.

Member overcharges are documented

CMS notices identify drug cost and subsidy adjustment failures affecting enrollee payments. Those are direct member-impact findings, separate from diagnosis-code audits. Primary source

Audit estimates are not paid penalties

OIG’s recommendations for H1036 and H5216 concern estimated overpayments. Humana disputed findings or recommendations. They cannot be presented as fines already paid.

Staffing effects need more evidence

Severance costs establish restructuring activity. They do not reveal which roles were eliminated, service consequences or whether the same jobs were later advertised.

01 / Financial accountability

Fines, settlements and audit findings.

Amounts retain their original category and payment status. There is no combined “fines paid” total.

2022-11-30 · HumanaFine / Medicare Parts C and D$131,660

CMS imposed; payment and appeal disposition not confirmed

CMS found enrollee overcharges and failures involving drug cost tracking, claims adjustments and cost sharing.

Primary source

2025-01-17 · HumanaFine / Medicare Part D$99,064

CMS imposed; payment and appeal disposition not confirmed

Delayed low-income subsidy claims adjustments and refunds caused drug overcharges.

Primary source

2021 · Humana, contract H1036Audit recommendation / Medicare Advantage$197,720,651

Refund recommended; not a paid fine

OIG estimated overpayments from unsupported diagnosis codes for payment year 2015.

Humana disputed aspects of the audit. The estimate is not a settlement or confirmed refund.

Primary source

2026-09 · HumanaChoice, contract H5216Audit recommendation / Medicare Advantage$130,900,000

Refund recommended; payment not confirmed

OIG estimated at least $130.9 million in 2020–2021 overpayments; 178 of 220 sampled enrollee-years had unsupported codes.

Humana disagreed with some findings and all recommendations. Rounded estimate; do not combine with fines paid.

Primary source

02 / Public contracts

Contract awards, losses and exits.

Intent to award is identified separately from final selection and an operational contract. Announcement dates may differ from service start dates.

DateState / programOutcome / statusRecord
2024-12-02Georgia
Georgia Families		Intent to award
Protest phase; NOA pending in state update of 2026-04-23		Apparent selection. Existing contracts extended through June 2027; implementation not confirmed.
Primary source
2023-06-08Oklahoma
SoonerSelect		Award
Award announced; launch expected April 2024 in notice		Medical managed care selection, subject to CMS approval at announcement.
Primary source
2023-02-01Ohio
Next Generation Medicaid		Selected / launched
State confirms program launch		Listed among participating plans in Ohio launch announcement.
Primary source
2023-03-08Indiana
PathWays for Aging		Recommended award
Recommended selection in announcement		Planned 2024 launch for long-term services and supports; final contract status not independently verified in this collection.
Primary source
03 / Workforce

Reductions and staffing questions.

Costs below are disclosed accounting charges. They are not fines, employee counts or proof of a care impact.

YearDisclosed costWhat is establishedSource
2023$199,000,000Severance and employee-related costs disclosed for workforce optimization / value creation initiatives. These are accounting costs, not numbers of eliminated jobs.Primary source
2024$25,000,000Severance and employee-related costs disclosed for workforce optimization / value creation initiatives. These are accounting costs, not numbers of eliminated jobs.Primary source
2025$329,000,000Severance and employee-related costs disclosed for workforce optimization / value creation initiatives. These are accounting costs, not numbers of eliminated jobs.Primary source
Layoffs followed by the same job postings: not yet verified.

Matching requires the employing entity, duties, location, job title, requisition and dated layoff notice and advertisement. General hiring after layoffs does not establish that the same positions were replaced.

04 / Executive leadership

Pay, benefits and turnover.

2025 named executive compensation

Reported SEC summary compensation totals include grant-date stock and option values. These are not cash take-home pay. Roles reflect the 2025 disclosure; partial-year and former executives are included.

Executive / disclosed roleSalaryAll other compensationReported total
Jim Rechtin
CEO		$1,348,558$505,636$18,757,075
Celeste Mellet
CFO		$900,000$43,935$18,922,704
Susan Diamond
Former CFO		$961,075$196,855$2,382,930
Japan Mehta
Executive		$618,750$4,123$9,564,563
Michelle O’Hara
Executive		$715,385$24,077$8,942,638
Sanjay Shetty
Executive		$715,769$163,520$7,155,679

2026 proxy: Summary Compensation Table. Full components are in the workbook.

CEO compensation history collected so far

YearExecutiveReported totalContext
2021Bruce Broussard$16,528,036
2022Bruce Broussard$17,198,844
2023Bruce Broussard$16,327,384
2024Bruce Broussard$12,057,164CEO through June 2024
2024Jim Rechtin$15,579,476CEO from July; SCT value used rather than PvP figure differing by $1
2025Jim Rechtin$18,757,075

Earlier-year extraction is incomplete. Missing years are not zero compensation; see research gaps below.

Selected benefits and other compensation components

Executive2025 componentAmount
Jim RechtinRetirement equalization$220,653
Jim RechtinRetirement match$26,250
Jim RechtinPersonal aircraft$143,304
Jim RechtinCharitable contributions$40,000
Jim RechtinFinancial planning$18,000
Jim RechtinOther$57,429

Components are already included in all other compensation; do not add them to reported total pay. Coverage of detailed benefits is partial.

Documented leadership changes

Effective / announcement dateRoleChange / source
2024-07-01CEOJim Rechtin succeeded Bruce Broussard in a planned transition.
Primary source
2024-12-03 announcementCFOCeleste Mellet named to succeed Susan Diamond; Diamond transitioned to an advisory role in 2025.
Primary source
Sources, methods and limits

A collection readers can check.

Research window: January 2020–October 6, 2026. Earlier conduct is included when an action was announced during the window. Sources prioritize regulators, state procurement notices, SEC filings and company disclosures. Company award announcements are identified as such.

Subsidiaries are grouped under their parent, with the entity and business identified. Former subsidiaries are labeled. A source link appears with each record. Reporting an allegation is not a finding of liability.

  • Initial collection, not a complete inventory of every action, subsidiary or procurement from 2020–2026.
  • Payment confirmation and appeal dispositions remain incomplete; assessed or agreed amounts are not described as paid.
  • Earlier executive compensation extraction is incomplete: 2020 all companies; 2021 CVS; 2022 UnitedHealth. Earlier non-CEO pay and benefits remain to be extracted.
  • 2026 annual executive compensation is not yet reported for a completed fiscal year. Positions in the 2025 pay table reflect that disclosure, not a current leadership directory.
  • CVS detailed benefit breakdown remains to be extracted. All other compensation is not synonymous with benefits; it can include severance and other items.
  • No matched evidence establishes elimination and later reposting of the same positions. Need job title, requisition, duties, location, employing entity and dated notices/postings.
  • Initial contract collection is selective. No Humana contract loss is documented here; that is a coverage gap, not proof that none occurred.
  • Pharmacy, PBM, employer insurance and workers compensation actions are labeled separately from Medicaid / Medicare health-plan actions.
  • Unequal search coverage and company size prevent a defensible ranking of companies by the counts or amounts in this collection.

Analysis expresses questions and inferences from the listed records. It does not establish causation between executive pay, staffing changes and member outcomes.

The record at a glance

Historical base: October 6, 2026, with dated targeted updates in the source records. Coverage is incomplete and differs by company. These charts are not rankings of conduct. Zero means no qualifying record in this collection.

Financial action records

Audit recommendation2
Fine / penalty2
Proposed nonmonetary consent0
Repayment0
Settlement0

Counts by type in this collection. Assessments, agreements and audit recommendations are separate; these are not fines paid.

Explore data and primary sources

Contract outcome records

Awards / selections / renewals4
Losses / exits / nonrenewals0

Selections may be tentative. Counts are not contract values or market share.

Explore data and primary sources